Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorVivanco-Hidalgo, Rosa M.
dc.contributor.authorMartinez, Elisenda
dc.contributor.authorRoman-Viñas, Ramón
dc.contributor.authorSánchez Montalvá, Adrián
dc.contributor.authorFibla, Joan
dc.contributor.authorMolina Romero, Israel
dc.date.accessioned2021-07-19T12:58:51Z
dc.date.available2021-07-19T12:58:51Z
dc.date.issued2021-03-04
dc.identifier.citationVivanco-Hidalgo RM, Molina I, Martinez E, Roman-Viñas R, Sánchez-Montalvá A, Fibla J, Pontes C, Velasco Muñoz C; Real World Data Working Group. Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020. Euro Surveill. 2021 Mar;26(9):2001202.
dc.identifier.issn1025-496X
dc.identifier.urihttps://hdl.handle.net/11351/6182
dc.descriptionCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cloroquina; Hidroxicloroquina
dc.description.sponsorshipNo funding was obtained for this study. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.
dc.language.isoeng
dc.publisherEuropean Centre for Disease Prevention and Control
dc.relation.ispartofseriesEurosurveillance;26(9)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia) - Catalunya
dc.subjectMedicaments antivírics - Efectes secundaris
dc.subject.meshCoronavirus Infections
dc.subject.meshIncidence
dc.subject.meshAntiviral Agents
dc.subject.mesh/adverse effects
dc.titleIncidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2807/1560-7917.ES.2021.26.9.2001202
dc.subject.decsinfecciones por Coronavirus
dc.subject.decsincidencia
dc.subject.decsantivíricos
dc.subject.decs/efectos adversos
dc.relation.publishversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.9.2001202
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Vivanco-Hidalgo RM, Martinez E, Roman-Viñas R] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut Generalitat de Catalunya, Carrer de Roc Boronat 81-95, Barcelona, Spain. [Molina I, Sánchez-Montalvá A] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fibla J] Unitat de Genètica Humana, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Av. Alcalde Rovira Roure, 80, Lleida, Spain. Institut de Recerca Biomedica de Lleida, Av. Alcalde Rovira Roure, 80, Lleida, Spain
dc.identifier.pmid33663646
dc.identifier.wos000626069000003
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple